York, PA, United States of America

Thomas J Atkins



Average Co-Inventor Count = 2.9

ph-index = 9

Forward Citations = 591(Granted Patents)


Location History:

  • Cincinnati, OH (US) (1997 - 1998)
  • York, PA (US) (1999 - 2009)

Company Filing History:


Years Active: 1997-2009

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovations of Thomas J Atkins: A Pioneer in Sustained-Release Microparticle Technology

Introduction

Thomas J Atkins is an accomplished inventor based in York, Pennsylvania, recognized for his significant contributions to the field of drug formulation. With an impressive portfolio of 11 patents, his work primarily focuses on innovative microparticle compositions that enhance the delivery and efficacy of pharmaceutical agents.

Latest Patents

One of Atkins' latest patents involves the development of microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles. This sustained-release microparticle composition can provide extended release over a period ranging from approximately 7 days to 200 days. The formulation includes biodegradable and biocompatible polymers, along with active agents like risperidone and its acid addition salts. In addition, this innovative microparticle composition is designed to offer multi-phasic release profiles, with some microparticles featuring more than one release rate, while others exhibit diffusional release as well as biodegradation release.

Career Highlights

Throughout his career, Thomas J Atkins has made significant strides while working for various reputable companies. Notably, he has contributed his expertise to Alkermes Controlled Therapeutics, Inc. and Janssen Pharmaceutica. His experience in these firms has played a pivotal role in shaping his innovative approach to pharmaceutical formulations.

Collaborations

Atkins has collaborated with notable professionals in the field, including Jean Louis Mesens and Michael E. Rickey. These partnerships have enabled him to further enhance his research and development efforts, leading to groundbreaking innovations in sustained-release technologies.

Conclusion

Thomas J Atkins continues to be a pioneering force in the realm of pharmaceutical innovations. His patents and contributions to sustained-release microparticle compositions demonstrate his commitment to advancing drug delivery systems that can ultimately improve patient outcomes. As the pharmaceutical landscape evolves, Atkins' work remains a testament to the importance of continuous innovation in this critical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…